Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man
- PMID: 3912192
- DOI: 10.1007/BF00613465
Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man
Abstract
Budesonide, a topically potent glucocorticoid, was administered to 4 healthy volunteers by i.v. infusion and by nasal instillation of 100 micrograms tritium-labelled drug. Plasma was analyzed by liquid chromatography plus scintillation counting of collected fractions. After i.v. administration the plasma clearance was 0.921/min and the apparent volume of distribution was 2.81/kg. After nasal administration, the time to reach the peak plasma level was approximately 30 min, and the systemic availability was 102%. Budesonide had marginal effects on plasma cortisol and white blood cell counts either after i.v. or nasal administration. Thus, nasally instilled budesonide in solution is rapidly and completely absorbed from the nasal mucosa. The systemic effects after this clinically recommended nasal dose were negligible.
Similar articles
-
Kinetics of the epimeric glucocorticoid budesonide.Clin Pharmacol Ther. 1984 Apr;35(4):525-30. doi: 10.1038/clpt.1984.71. Clin Pharmacol Ther. 1984. PMID: 6705451
-
A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler.Eur J Clin Pharmacol. 1997;52(4):261-7. doi: 10.1007/s002280050287. Eur J Clin Pharmacol. 1997. PMID: 9248762 Clinical Trial.
-
Systemic effects of two nasally administered glucocorticosteroids.Allergy. 1997 Jun;52(6):620-6. doi: 10.1111/j.1398-9995.1997.tb01040.x. Allergy. 1997. PMID: 9226055 Clinical Trial.
-
Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.Drugs. 1984 Dec;28(6):485-518. doi: 10.2165/00003495-198428060-00001. Drugs. 1984. PMID: 6394263 Review.
-
Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.Drugs. 1995 Nov;50(5):854-72. doi: 10.2165/00003495-199550050-00006. Drugs. 1995. PMID: 8586030 Review.
Cited by
-
Clinical pharmacokinetics of inhaled budesonide.Clin Pharmacokinet. 2001;40(6):427-40. doi: 10.2165/00003088-200140060-00004. Clin Pharmacokinet. 2001. PMID: 11475468 Review.
-
Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.Br J Clin Pharmacol. 2000 Aug;50(2):116-24. doi: 10.1046/j.1365-2125.2000.00218.x. Br J Clin Pharmacol. 2000. PMID: 10930963 Free PMC article. Clinical Trial.
-
The impact of corticosteroids on growth and bone health.Arch Dis Child. 2002 Aug;87(2):93-6. doi: 10.1136/adc.87.2.93. Arch Dis Child. 2002. PMID: 12138051 Free PMC article. No abstract available.
-
A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis.Drug Saf. 2000 Oct;23(4):309-22. doi: 10.2165/00002018-200023040-00004. Drug Saf. 2000. PMID: 11051218 Review.
-
Rectal pharmacokinetics of budesonide.Eur J Clin Pharmacol. 1996;49(4):293-8. doi: 10.1007/BF00226330. Eur J Clin Pharmacol. 1996. PMID: 8857075 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources